Belgrade

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis2 trials
• Myasthenia gravis2 trials
• Chronic myeloid leukaemia1 trial
• Familial hypercholesterolaemia1 trial
• High blood pressure1 trial
• Pulmonary arterial hypertension1 trial

Phase

• Phase 36 trials
• Phase 1/21 trial

Status

• Active, not recruiting5 trials
• Completed1 trial
• Recruiting1 trial

Lead sponsor

• Novartis Pharmaceuticals7 trials

Running trials

• Active, not recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

  NCT06744920· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

  NCT06649110· Phase 1/2· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

  NCT06517758· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

  NCT04926818· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

  NCT01892722· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• High blood pressure1 recruiting
• Pulmonary arterial hypertension1 recruiting

Closed trials

• Completed

  Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

  NCT03106779· Phase 3· Novartis Pharmaceuticals· Source